Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
187.86
+5.24 (2.87%)
Feb 21, 2025, 4:00 PM EST - Market closed
Krystal Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Revenue | 290.52 | 50.7 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | 473.02% | - | - | - | - | Upgrade
|
| Cost of Revenue | 20.06 | 3.09 | - | - | - | Upgrade
|
| Gross Profit | 270.45 | 47.61 | - | - | - | Upgrade
|
| Selling, General & Admin | 113.69 | 98.4 | 78.84 | 41.99 | 15.06 | Upgrade
|
| Research & Development | 53.57 | 46.43 | 42.46 | 27.88 | 17.94 | Upgrade
|
| Operating Expenses | 167.26 | 144.83 | 121.3 | 69.88 | 33 | Upgrade
|
| Operating Income | 103.2 | -97.23 | -121.3 | -69.88 | -33 | Upgrade
|
| Interest Expense | - | - | - | -1.49 | - | Upgrade
|
| Interest & Investment Income | 29.66 | 22.62 | 5.22 | 0.2 | 0.83 | Upgrade
|
| EBT Excluding Unusual Items | 132.86 | -74.6 | -116.08 | -71.17 | -32.17 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 100 | - | - | - | Upgrade
|
| Legal Settlements | -37.5 | -12.5 | -25 | - | - | Upgrade
|
| Pretax Income | 95.36 | 12.9 | -139.98 | -69.57 | -32.17 | Upgrade
|
| Income Tax Expense | 6.2 | 1.97 | - | - | - | Upgrade
|
| Net Income | 89.16 | 10.93 | -139.98 | -69.57 | -32.17 | Upgrade
|
| Net Income to Common | 89.16 | 10.93 | -139.98 | -69.57 | -32.17 | Upgrade
|
| Net Income Growth | 715.58% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 29 | 27 | 25 | 22 | 19 | Upgrade
|
| Shares Outstanding (Diluted) | 30 | 28 | 25 | 22 | 19 | Upgrade
|
| Shares Change (YoY) | 7.16% | 8.87% | 14.85% | 18.15% | 18.15% | Upgrade
|
| EPS (Basic) | 3.12 | 0.40 | -5.49 | -3.13 | -1.71 | Upgrade
|
| EPS (Diluted) | 3.00 | 0.39 | -5.49 | -3.13 | -1.71 | Upgrade
|
| EPS Growth | 669.23% | - | - | - | - | Upgrade
|
| Free Cash Flow | 119.18 | -100.6 | -153.55 | -116.27 | -40.93 | Upgrade
|
| Free Cash Flow Per Share | 4.01 | -3.63 | -6.02 | -5.24 | -2.18 | Upgrade
|
| Gross Margin | 93.09% | 93.90% | - | - | - | Upgrade
|
| Operating Margin | 35.52% | -191.77% | - | - | - | Upgrade
|
| Profit Margin | 30.69% | 21.56% | - | - | - | Upgrade
|
| Free Cash Flow Margin | 41.02% | -198.43% | - | - | - | Upgrade
|
| EBITDA | 109.16 | -92.22 | -118.65 | -67.11 | -31.15 | Upgrade
|
| EBITDA Margin | 37.58% | -181.90% | - | - | - | Upgrade
|
| D&A For EBITDA | 5.97 | 5.01 | 2.64 | 2.77 | 1.85 | Upgrade
|
| EBIT | 103.2 | -97.23 | -121.3 | -69.88 | -33 | Upgrade
|
| EBIT Margin | 35.52% | -191.77% | - | - | - | Upgrade
|
| Effective Tax Rate | 6.50% | 15.24% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.